文献速递胸部病理细胞病理与分子病理

肺癌小活检与细胞学中的分子检测:世界逻辑

Lung cancer and molecular testing in small biopsies versus cytology: The Logics of Worlds.
PubMed 文献 · Cancer Cytopathol · 2020-01-01

本文基于2019年那不勒斯第8届国家分子细胞病理学会议,聚焦细胞学样本中肺癌生物标志物检测的更新。肺癌常因无法手术而依赖细胞学诊断与治疗诊断检测,会议讨论了细胞病理学在分子检测中的新角色与趋势,并引用相关文献,探讨其对病理实践的意义。

要点

  • 肺癌常无法手术获取组织,细胞学样本用于诊断与治疗诊断检测。
  • 会议聚焦细胞学样本中肺癌生物标志物检测的更新与分子分类。
  • 细胞病理学在分子检测中角色更新,影响病理实践趋势。

核心结论

  • 细胞学样本在肺癌诊断与治疗诊断检测中具有重要作用,分子检测更新影响病理实践。

主要发现

  • 肺癌仍是全球最常诊断的非皮肤恶性肿瘤。
  • 多数肺癌患者确诊时无法手术获取组织,导致使用细胞学进行诊断和治疗诊断检测。
  • 会议讨论了细胞病理学在分子检测中的新角色与更新,以引发新趋势和新方法。

临床怎么用

  • 在肺癌无法手术获取组织时,可采用细胞学样本进行诊断和治疗诊断检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 8th Annual National Molecular Cytopathology Meeting, held in Naples, Italy, on December 2 to 3, 2019, addressed updates in diagnostic cytopathology and molecular classifications and specifically focused on lung cancer biomarker testing in cytology samples. Lung cancer continues to be the most commonly diagnosed noncutaneous malignancy in the world. In the majority of patients, lung cancers are frequently identified when they cannot be surgically accessed, and this leads to the use of cytology for a diagnosis and theragnostic testing. The meeting was an international forum for discussing new roles and updates for cytopathology in molecular testing as the basis for provoking new trends and novel approaches. The relevant literature is referenced. The significance of these updates for the practice of pathology in general is discussed.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Rossi ED, Wiles A, Vecchione A, et al. Lung cancer and molecular testing in small biopsies versus cytology: The Logics of Worlds. Cancer Cytopathol. 2020. PMID: 32885910. doi:10.1002/cncy.22291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。